Gold nanoparticles may help earlier liver cancer diagnosis

Twitter icon
Facebook icon
LinkedIn icon
e-mail icon
Google icon

Researchers are reporting promising results for earlier diagnosis of liver cancer. In lab tests, the team used gold nanoparticles ringed by a charged polymer coating and an x-ray scatter imaging technique to spot tumor-like masses as small as 5 mm. The approach, published June 6 in Nano Letters, is reportedly the first time that metal nanoparticles have been used as agents to enhance x-ray scattering signals to image tumor-like masses.

Hepatocellular carcinoma is the most common cancer to strike the liver. More than 500,000 people globally, concentrated in sub-Saharan Africa and Southeast Asia, are diagnosed with it yearly. Most of those afflicted die within six months. A big obstacle to treatment of liver cancer is the lack of early diagnosis. Current techniques, including ultrasound, CT and MRI scans, spot tumors only when they have grown to about 5 cm in diameter. By that time, the cancer is especially aggressive, resisting chemotherapy and difficult to remove surgically, according to the researchers.

"What we're doing is not a screening method," said corresponding author Christoph G. F. Rose-Petruck, PhD, associate professor of chemistry at Brown University in Providence, R.I. "In a routine exam, with people who have risk factors, such as certain types of hepatitis, we can use this technique to see a tumor that is just a few millimeters in diameter, which, in terms of size, is a factor of 10 smaller."

The team took gold nanoparticles of 10 and 50 nanometers in diameter and ringed them with a pair of 1 nanometer polyelectrolyte coatings. The coating gave the nanoparticles a charge, which increased the chances that they would be engulfed by the cancerous cells. Once engulfed, the team used x-ray scatter imaging to detect the gold nanoparticles within the malignant cells.

In lab tests, the investigators reported that the nontoxic gold nanoparticles made up just 0.0006 percent of the cell's volume, yet the nanoparticles had enough critical mass to be detected by the x-ray scatter imaging device.

"We have shown that even with these small numbers, we can distinguish these [tumor] cells," Rose-Petruck said.

The next step is on the clinical side. Beginning this summer, the group will attach a cancer-targeting antibody to the nanoparticle vehicle to search for liver tumors in mice. The antibody that will be used was developed by Jack R. Wands, MD, director of the Liver Research Center at Rhode Island Hospital in Providence, R.I., and professor of medical science at Brown University's Warren Alpert Medical School, also in Providence, R.I.

"We have developed a monoclonal antibody that targets a cell surface protein highly expressed on liver cancer cells," Wands said. "We plan to couple the antibody to the gold nanoparticles in an attempt to detect the growth of early tumors in the liver by x-ray imaging."

The researchers said the x-ray scatter imaging method could be used to detect nanoparticle assemblies in other organs. "The idea should be that if you can figure out to get that [nanoparticle] to specific sites in the body, you can figure out how to image it," said lead author Danielle Rand, a second-year graduate student in chemistry at Brown.

The National Institutes of Health and the U.S. Department of Energy funded the research.